Kidney disease drug trial explores how EC5026 moves through the body
NCT ID NCT07694544
First seen Jul 10, 2026 · Last updated Jul 10, 2026
Summary
This Phase 1 trial investigates how a single 8 mg dose of EC5026 is processed by the body in adults aged 55 and older with chronic kidney disease (stages 3b to 5, not on dialysis) compared to healthy adults with normal kidney function. Researchers will measure drug levels in blood and urine over 14 days to understand how kidney impairment affects the drug's breakdown and removal. The study also monitors safety and tolerability through physical exams, vital signs, and electrocardiograms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- EC5026 oral tablet
- What this could lead to
- If successful, this study could help determine safe dosing of EC5026 for people with kidney disease, potentially opening the door to future treatments.
- What could go wrong
- This is an early Phase 1 trial with only 18 participants, so results may not apply broadly. The drug may behave differently in larger or more diverse groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UC Davis Medical Center
RECRUITINGSacramento, California, 95817, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Aging kidneys under the microscope: could a simple test predict failure?
- Could your gut bacteria hold the key to protecting your kidneys?
- Food as medicine: could cooking classes slow kidney disease?
- Could a phone app be the key to managing kidney disease?
- A new pill aims to slow kidney failure and save lives
- AI takes on kidney disease: a new model to forecast Who's at risk